J Cancer 2018; 9(1):174-181. doi:10.7150/jca.21605

Research Paper

Exploration of the optimal treatment regimes for Esthesioneuroblastoma: a single center experience in China

Yujie Yuan2*, Jinning Ye2*, Huizhi Qiu3*, Shaoqing Niu1, Bixiu Wen2, Dongping Wang4✉, Xinping Cao5✉, Yufeng Ren1✉

1. Department of Radiation Oncology, The First Affiliated Hospital, Sun Yat-sen University;
2. Center of Gastrointestinal Surgery, The First Affiliated Hospital, Sun Yat-sen University;
3. Department of Radiotherapy, cancer center of Guangzhou medical university, Guangzhou 510080, P.R. China;
4. Department of Organ transplantation, The First Affiliated Hospital, Sun Yat-sen University;
5. Department of Radiation Oncology, Cancer Center of Sun Yat-sen University, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine.
* These authors contributed equally to this work.

Abstract

BACKGROUND: Esthesioneuroblastoma (ENB) is an uncommon neoplasm arising from the olfactory mucosa. The optimal treatment regimen for ENB remains unclear. This study aims to evaluate its clinical features, long-term outcomes and explore optimal treatment patterns.

METHODS: Clinical data of consecutive 44 ENB patients were reviewed retrospectively. The correlation between clinical features and treatment approaches were analyzed, with several prognostic factors explored meanwhile.

RESULTS: The age of onset of ENB showed a bimodal distribution, with peaks at 10~20 and 50~60 years. The median follow-up time was 84 months (range, 27~198 months).The 5-year overall and progression free survival rates were 42.7% and 39.1%, respectively, with 10-year rates of 28.9% and 21.7% respectively. Overall, 19 patients developed recurrent disease. Patients undergoing surgery combined with adjuvant radiotherapy had significantly higher 5-year overall survival (67.5% vs. 33.3%, P=0.043) and progress-free survival (60.0%vs. 18.7%, P=0.008) than those receiving other treatment approaches. No-Skin-involved ENB was associated with markedly better 5-year overall survival (45.5%vs.0 %, P=0.038) and progress-free survival (31.3% vs. 0 %, P=0.001) compared with skin-involved tumor.

CONCLUSIONS: ENB is a rarely malignant tumor with high probability of locoregional recurrence and poor survival. Surgical resection followed by radiotherapy has been shown to achieve optimal local control and overall survival.

Keywords: Esthesioneuroblastoma, Multimodality, Surgery, Radiotherapy, Survival.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Yuan Y, Ye J, Qiu H, Niu S, Wen B, Wang D, Cao X, Ren Y. Exploration of the optimal treatment regimes for Esthesioneuroblastoma: a single center experience in China. J Cancer 2018; 9(1):174-181. doi:10.7150/jca.21605. Available from http://www.jcancer.org/v09p0174.htm